NCT00955383View on ClinicalTrials.gov

GSK2190915 Safety and Pharmacokinetic Study in Healthy Japanese Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

August 14, 2009

Primary Completion Date

October 12, 2009

Study Completion Date

October 12, 2009

Conditions

Asthma

Interventions

DRUG

GSK2190915

GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.

DRUG

Placebo

Matching placebo

Trial Locations (1)

41460

GSK Investigational Site, Neuss

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY